Lobbying Disclosure Act Guidance Reverses Course!
Client Alert | 1 min read | 07.16.08
The Secretary of the Senate and Clerk of the House overhauled Section 7 of The Lobbying Disclosure Act Guidance regarding required contribution disclosures (due July 30). Several examples in the most recent Guidance represent a complete reversal from those posted in the May 29, 2008 iteration.
For example, the prior Guidance stated that the mere recognition of a covered official as an "honorary co-host" was sufficient to trigger reporting requirements. Example 7 now provides the opposite.
The prior Guidance also suggested that one must disclose mere payment for a ticket to a luncheon at which a covered official is honored. Example 9 now states that buying a ticket or table to another entity's dinner event is not in itself a reportable circumstance.
In addition, the prior Guidance stated that lobbying registrants must disclose their financial sponsorship of an event when a covered official is merely a speaker or disclosed invitee. Examples 6 and 8 of the Guidance now state that unless the covered official receives a special award, honor, or recognition in connection with such an event, the cost of the event need not be disclosed.
Other minor amendments include a clarification that events must be disclosed where a covered official is bestowed an award, even if the primary purpose of the event is other than to honor the official (e.g., to raise money for the sponsoring organization).
For a copy of the new Guidance, click here:
http://lobbyingdisclosure.house.gov/amended_lda_guide.html
Insights
Client Alert | 4 min read | 04.08.26
Cosmetics Under the Microscope: FDA’s Expanding Regulatory Reach Under MoCRA
The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) marked the most significant expansion of FDA’s authority over cosmetics in 80 years — and the agency is putting that authority to work. From the launch of a new adverse event reporting tool to forthcoming rules on fragrance allergens and good manufacturing practices (GMP), FDA is reshaping the regulatory landscape for manufacturers, packers, and distributors of cosmetic and personal care products.
Client Alert | 11 min read | 04.08.26
Client Alert | 3 min read | 04.07.26
Answering the Top Seven Questions About Pending Section 301 Deadlines
